Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $27.4286.

Several research firms have weighed in on STOK. Weiss Ratings reissued a “sell (d+)” rating on shares of Stoke Therapeutics in a research note on Wednesday, October 8th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They set a “buy” rating and a $30.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Needham & Company LLC upped their price objective on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research note on Friday. Finally, BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the company a “buy” rating in a research note on Monday, August 18th.

Stoke Therapeutics Stock Up 1.0%

Stoke Therapeutics stock opened at $30.19 on Wednesday. The company has a market capitalization of $1.65 billion, a PE ratio of 35.52 and a beta of 1.24. The firm has a fifty day simple moving average of $20.97 and a two-hundred day simple moving average of $13.92. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $32.40.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. The business had revenue of $13.82 million during the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. As a group, equities analysts expect that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Activity

In related news, General Counsel Jonathan Allan sold 14,922 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $20.14, for a total value of $300,529.08. Following the completion of the transaction, the general counsel directly owned 18,176 shares of the company’s stock, valued at $366,064.64. This represents a 45.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Barry Ticho sold 5,501 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the completion of the transaction, the insider directly owned 18,469 shares of the company’s stock, valued at approximately $366,979.03. The trade was a 22.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 185,180 shares of company stock valued at $4,129,406. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its holdings in Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after purchasing an additional 5,084 shares during the period. BNP Paribas Financial Markets grew its holdings in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the period. Tower Research Capital LLC TRC grew its holdings in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period. AlphaQuest LLC purchased a new stake in Stoke Therapeutics in the first quarter worth about $72,000. Finally, US Bancorp DE grew its holdings in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after purchasing an additional 11,108 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.